Methylation of the RASSF1A, RARβ2, and SEMA3B genes in epithelial breast and ovarian tumors, and in patients with polyneoplasia
| Autor: | T. P. Kazubskaya, V. I. Loginov, D. S. Khodyrev, V. D. Ermilova, Yu. G. Payanidi, N. V. Chkhikvadze, V. Yu. Selchuk, E. A. Braga |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2014 |
| Předmět: | |
| Zdroj: | Опухоли женской репродуктивной системы, Vol 0, Iss 1, Pp 61-68 (2014) |
| Druh dokumentu: | article |
| ISSN: | 1994-4098 1999-8627 |
| DOI: | 10.17650/1994-4098-2012-0-1-61-68 |
| Popis: | The methylation status of the tumor suppressor genes RASSF1A, RARβ2, and SEMA3B was studied in the samples of cancer and its histologically normal tissue of the breast and ovaries. The high rate of abnormal methylation of the CpG islet in the RASSF1A, RARβ2, and SEMA3B genes was found in the tumors of the breast (78% (32/41), 46% (26/56), and 35% (22/65), respectively) and ovaries 73% (33/45), 30% (15/50), and 50% (25/51). Hypermethylation in the CpG islets belonging to the RASSF1A and RARβ2 genes was first ascertained in 90% of the patients with polyneoplasms involving the breast and ovaries. Abnormal methylation of the promotor region of the RASSF1A gene was shown to be detectable in preclinical-stage and anaplasia-degree breast and ovarian cancer. There was a correlation of the rate of methylation in the promoter regions of the RARβ2 and SEMA3B genes with clinical-stage and anaplasia-degree breast and ovarian cancer. Analysis of gene methylation in biological fluids provides considerable opportunity to use methylation of DNA as a marker in clinical practice. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|